| 000 | 00945 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250517201826.0 | ||
| 264 | 0 | _c20190412 | |
| 008 | 201904s 0 0 eng d | ||
| 022 | _a1365-2036 | ||
| 024 | 7 |
_a10.1111/apt.14509 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan Bodegraven, A A | |
| 245 | 0 | 0 |
_aEditorial: nocebo effect and switching to biosimilars. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _c03 2018 |
||
| 300 |
_a850-851 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 | _aBiosimilar Pharmaceuticals |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInflammatory Bowel Diseases |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aNocebo Effect |
| 650 | 0 | 4 | _aProspective Studies |
| 700 | 1 | _aBoone, N W | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 47 _gno. 6 _gp. 850-851 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/apt.14509 _zAvailable from publisher's website |
| 999 |
_c28088457 _d28088457 |
||